Chevallier Patrice, Roland Virginie, Mahé Béatrice, Juge-Morineau Nadine, Dubruille Viviane, Guillaume Thierry, Vigouroux Stéphane, Moreau Philippe, Milpied Noël, Garand Richard, Avet-Loiseau Herve, Harousseau Jean-Luc
Service d'Hématologie Clinique, Centre Hospitalier Universitaire, 9 quai Moncousu, BP1005, 44093 Nantes Cedex 01, France.
Leuk Res. 2005 Sep;29(9):1003-7. doi: 10.1016/j.leukres.2005.02.005. Epub 2005 Apr 8.
We have used the dose of 9 mg/m(2) of mylotarg 4 days after the beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM) in 17 patients with refractory (n=4) or relapsed (n=13) AML. Thirteen patients (76%) achieved CR (n=12) or partial CR (n=1). All four refractory patients and all four patients with poor risk cytogenetic achieved CR or CRp. Although the dose of mylotarg given in combination with chemotherapy was not reduced, the toxicity profile was acceptable (1VOD/17 patients). The MIDAM protocol appears to be highly effective especially in patients with poor risk cytogenetic and/or refractory disease.
我们在17例难治性（n = 4）或复发性（n = 13）急性髓系白血病（AML）患者中，于开始使用包含中剂量阿糖胞苷和米托蒽醌（MIDAM）的化疗方案4天后，使用了9 mg/m²的米哚妥林剂量。13例患者（76%）达到完全缓解（CR，n = 12）或部分缓解（n = 1）。所有4例难治性患者以及所有4例细胞遗传学风险不良的患者均达到CR或CRp（部分缓解伴血液学完全缓解）。尽管与化疗联合使用的米哚妥林剂量未降低，但其毒性反应情况是可接受的（17例患者中有1例发生静脉闭塞性疾病）。MIDAM方案似乎具有很高的疗效，尤其对于细胞遗传学风险不良和/或难治性疾病的患者。
